The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 510,731 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 506.74% since March 7, 2016 and is uptrending. It has outperformed by 499.15% the S&P500.
The move comes after 5 months positive chart setup for the $42.32 million company. It was reported on Oct, 10 by Barchart.com. We have $7.07 PT which if reached, will make NASDAQ:EBIO worth $82.95 million more.
Analysts await Eleven Biotherapeutics Inc (NASDAQ:EBIO) to report earnings on November, 2.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. On Wednesday, March 16 the stock rating was maintained by Citigroup with “Neutral”. Leerink Swann downgraded the shares of EBIO in a report on Tuesday, January 19 to “Market Perform” rating. The firm has “Outperform” rating by Leerink Swann given on Saturday, August 15. The company was downgraded on Tuesday, January 19 by Citigroup.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.62, from 0.38 in 2016Q1. The ratio improved, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Goldman Sachs Gp has 0% invested in the company for 13,343 shares. Guggenheim Cap owns 10,331 shares or 0% of their US portfolio. The Ontario – Canada-based Retail Bank Of Montreal Can has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Royal Savings Bank Of Canada last reported 0% of its portfolio in the stock. Commercial Bank Of America De holds 35 shares or 0% of its portfolio. Moreover, Geode Cap Management Limited Liability Com has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 46,637 shares. Renaissance Technologies Limited Com accumulated 118,500 shares or 0% of the stock. Grp One Trading Limited Partnership holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 600 shares. Blackrock Fund Advsr holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 1,624 shares. Blackrock Institutional Tru Na has 0% invested in the company for 149,618 shares. The New Jersey-based Kcg Hldg has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Morgan Stanley last reported 0% of its portfolio in the stock. Comml Bank Of New York Mellon Corp owns 67,483 shares or 0% of their US portfolio. Flagship Ventures 2007 General Partner Ltd Liability Corp holds 2.98% or 1.91 million shares in its portfolio. Vanguard Group holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 77,656 shares.
More news for Eleven Biotherapeutics Inc (NASDAQ:EBIO) were recently published by: 247Wallst.com, which released: “Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?” on August 16, 2016. Marketwatch.com‘s article titled: “Eleven Biotherapeutics’ stock rockets after milestone payment announcement” and published on July 08, 2016 is yet another important article.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.